3De Feyter PJ, Van den Brand M, Jam-man G, et al. Acute coronary occlusion during and after percutaneous transluminal coronary angiop lasty [J]. Circulation, 1991, 83: 927-936. 被引量：1
4Lincoff AM, Popma JJ, Ellis SG, et al. Abrupt vessel closure complicating coronary angioplasty: Clinical, angiographic and therapeutic profile [J]. J Am Coil Cardiol, 1992, 19:926 -935. 被引量：1
5The EPIC investigators. Use of a monoclonal antibody directed against the platelet glycoprotein II b/III a receptor in high - risk coronary angioplasty [J]. N Engl J Med, 1994, 330: 956-961. 被引量：1
6Sekiguchi M, Hoshizaki H, Adachi H, et al. Effects of antip latelet agents on subacute thrombosis and restenosis after succossful coronary stenting: A randomized comparison of tlclopidine and cilostawl [ J]. Circ J, 2004, 68: 610-614. 被引量：1
7Elliott MA, Marc C, Peter JLMB, et al. The TIMI Risk Score for Unstable Angina/Non - ST ElevationMI : A Method for Prognostication and Therapeutic Decision Making [J]. JAMA, 2000, 284:835-842. 被引量：1
8The platelet receptor inhibition for ischemie syndrome management in patients limited by unstable signs and symp toms ( PRISM - PLUS) trial investigators. Inhibition of the platelet glyeoprotein II b/III a receptor with tirofiban in unstable angina and non - Q - wave myocardial infarction [J]. N Engl J Med, 1998, 38:1488 -1497. 被引量：1
9The platelet receptor inhibition for ischemic syndrome management ( PRISM ) study investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina [ J ]. N Engl JMed, 1998, 338:1498 - 1505. 被引量：1
10The platelet receptor inhibition for ischemic syndrome management ( PRISM) study investigators. A comparison of asp irin plustirofiban with asp ifin plus heparin for unstable angina [J]. N Engl J Med, 1998, 338: 1498-1505. 被引量：1
